Clinical trial
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma…
NCT00071084 · Genmab, Industry · Completed
Key facts
| NCT number | NCT00071084 |
|---|---|
| Title | Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. |
| Official title | An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Advanced Stage (IIA-IVB) Cutaneous T-cell Lymphoma |
| Lead sponsor | Genmab, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cutaneous T-Cell Lymphoma |
| Intervention type | Drug |
| Interventions | HuMax-CD4 |
| Enrollment | 22 |
| Start date | May 27, 2003 |
| Primary completion | Jun 29, 2004 |
| Completion | Jun 29, 2004 |
| First posted | Oct 15, 2003 |
| Last update posted | Apr 28, 2023 |
| Countries | Germany, Sweden, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: